Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered...
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial
About this item
Full title
Author / Creator
Chen, Haiping , Huang, Zhuoying , Chang, Shaoying , Hu, Mei , Lu, Qingbin , Zhang, Yuntao , Wang, Hui , Xiao, Yanhui , Ge, Yonghong , Zou, Yong , Cui, Fuqiang , Han, Shasha , Zhang, Min , Wang, Shengyi , Zhu, Xiaoping , Zhang, Biao , Li, Zhi , Ren, Jia , Chen, Xiao , Ma, Rui , Zhang, Lei , Guo, Xue , Luo, Linyun , Sun, Xiaodong and Yang, Xiaoming
Publisher
Netherlands: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
AbstractBackgroundThe safety and immunogenicity of the coadministration of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV), quadrivalent split-virion inactivated influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults in China is unknown. MethodsIn this open-label, non-inferiority, randomised controlle...
Alternative Titles
Full title
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9334936
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9334936
Other Identifiers
ISSN
0264-410X,1873-2518
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2022.07.033
